Intrinsiqq
Actuate Therapeutics Inc. logo

Actuate Therapeutics Inc. Financials

ACTU

Compare

All currency values in $ millions unless otherwise noted

Income Statement
DEC 2025
~2.5:1 split
DEC 2024
~5.8:1 split
DEC 2023
General & Administrative$12$6$3
Research & Development$10$19$22
Total Operating Expenses$22$25$25
Operating Income-$22-$25-$25
Non-Operating
Net Interest Expense$0$0$0
Other Non-Operating Income (Expense)$0-$2$0
Income Tax Expense$0$0$0
Net Income
Net Income-$22-$27-$25
EPS (Basic)-$1.06-$3.26-$17.24
EPS (Diluted)-$1.06-$3.26-$17.24
Weighted Avg Shares (Basic)21.0M8.4M1.4M
Weighted Avg Shares (Diluted)21.0M8.4M1.4M
Shares Outstanding21.0M8.4M1.4M

Actuate Therapeutics (ACTU) financials: revenue, profit and margins

Actuate Therapeutics (ACTU) generated about n/a in revenue and -$18 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Actuate Therapeutics profitable?+

Actuate Therapeutics reported about -$18 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 13 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 14 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ACTU

CompareIntrinsic value
ANVSAnnovis Bio, Inc.
$0.71-5.16%10
KTTAPasithea Therapeutics Corp.
$0.48-0.48%40
TPSTTempest Therapeutics Inc.
$0.29-5.36%0
PCSAProcessa Pharmaceuticals Inc.
$1.56-7.69%10
CPIXCumberland Pharmaceuticals Inc.
$5.84-7.30%20
GRIGri Bio Inc.
$1.12+0.00%20
PSTVPlus Therapeutics Inc
No recent price20
EVFMEvofem Biosciences Inc.
$1.00+0.00%15

Spot a number that looks wrong? Check it in ACTU's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ACTU

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.